Compounds > 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetic acid and clioquinol

3,4-dihydroxyphenylacetic acid has been researched along with clioquinol in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andersen, JK; Beal, MF; Boonplueang, R; Bush, AI; Cherny, RA; DiMonte, D; Ellerby, L; Jacobs, R; Kaur, D; Kumar, J; Mo, JQ; Rajagopalan, S; Viswanath, V; Volitaskis, I; Yang, L; Yantiri, F1
Adlard, PA; Appukuttan, AT; Ayton, S; Bush, AI; Finkelstein, DI; Lei, P; Volitakis, I1

Other Studies

2 other study(ies) available for 3,4-dihydroxyphenylacetic acid and clioquinol

ArticleYear
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
    Neuron, 2003, Mar-27, Volume: 37, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Western; Cell Death; Clioquinol; Dopamine; Ferritins; Gene Expression; Genetic Therapy; Homovanillic Acid; Humans; Immunohistochemistry; Iron; Iron Chelating Agents; Mice; Mice, Transgenic; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Promoter Regions, Genetic; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase

2003
Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.
    Neurobiology of disease, 2015, Volume: 81

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Clioquinol; Dementia; Disease Models, Animal; Dopamine; Maze Learning; Metals; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Muscle Strength; Neurons; Parkinsonian Disorders; Rotarod Performance Test; Substantia Nigra; tau Proteins; Tyrosine 3-Monooxygenase

2015